INVITRO- INVIVO EVALUATION OF CISPLATIN LOADED PLGA NANOPARTICLES

C. Subba Parameswari[1*], S. Umadevi[2]

Article History: Received: 02.10.2022 **Revised:** 23.12.2022 **Accepted:** 15.03.2023

Abstract:

This research work focused to evaluate the therapeutic efficiency of the drug impregnated into polylactide-co-glycolide- PLGA nano sized particles for the management of Ovarian malignancy. The nanosized formulation was lucratively developed by Double Emulsion Solvent Evaporation technique. The formulation optimization was done using CCRD-RSM and characterized in terms of stability studies, sterility studies, in-vitro cytotoxicit y effects, in-vivo anti-cancer activity and therapeutic possessions. The nanosized particles caused an increase in the cyto-toxicity effects of Cisplatin against Ovarian cell adeno carcinoma cells (A2786) (2.3-fold) when compared to the standard Cisplatin. The Nano formulation also made an increase in the therapeutic effects of Cisplatin by 1.8-fold, in which a reduction in the mean tumor size was seen when compared to the standard Cisplatin receiver mice. The IC50 worth of Cisplatin and C-PLGA intensifies on ovarian disease cells was 38.53 µg/ml and 24.6 µg/ml which is ~20 fold better compared to the parent compound Cisplatin. Our improved plan of C-PLGA compound was viewed as more deadly on A2780 malignant growth cells. Overall Cisplatin-loaded PLGA nanosized particles can be called as a absolute drug candidate for the management of cancer due toits potency to reducethe side effects of cisplatin andits toxicity and therapeuticeffects on Cancer-bearing Albino mice.

Keywords: Cisplatin, Ovarian Cancer Cells-A2780,Polylactideco-Glycolicacid,Albino Mice.

[1*]Research Scholar, De partment of Pharmaceutics, VEL S Un iversity, Chennai, TamilNadu, India-600117
[2]Associate Professor, Department of Pharmaceutics, VEL S Univers ity, Chennai, TamilNadu, India – 60 0117

Email: [1*]ramanampharmacy@gmail.com

DOI: 10.31838/ecb/2023.12.1.096

1. Introduction

Cisplatin is a platinum adopted cancer treatment ingredient dependent on platinum that is used to treat different forms of cancers. Targeted availability of cisplatin is therefore important for particular cancer cells to be able to show a means of altering the distribution of drug in vivo and rapid increase in its amount and target sites , enhancing safety and lowering toxicity. The goal of the current study was to deliver cisplatin using this carrier. The effectiveness of PLGA as a cisplatin carrier was assessed for this purpose in both in vitro and in vivo settings for the treatment of ovarian cancer. In this regard, the dialysis membrane method, 3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide(MTT) assay, and histopathological examinations were used to examine the cytotoxicity, in vivo toxicity, and therapeutic effects of the formulation. To assess the toxicity of the nanoformulation, further investigations, including blood parameter concentrations and their tumour size, were also conducted1.
TheCisplatin-PLGA nano particles were prepared by Double Solvent Emulsion method and the prepared particles were optimized using CCRD-RSM Methodology. The Optimized Formulation was considered for the further evaluation in this research work.[2]

2. Materials and Methods:

Cisplatin was procured from Waks man Sel man Pharmaceuticals Pvt . Ltd ., A nantapur, India. Ovarian epithelial carcinoma cell line A2780 was purchased from NCC S (India). D MEM-high Glucose , MT T reagent, bio chemical kits for quantification of serum and urine biomarkers were procured from the Himedia Laboratories, Mumbai, India. PLGA was acquired from Sigma-Aldrich (St. Louis, USA). Ingrained Swiss albino mice of two months old from College Animal House.

Stability Studies:
The following was determined about the storage stability of optimised nanoparticles. In a nutshell, an aliquot of a 15 ml nanoparticle suspension containing a 1 mg/ml drug concentration was put into glass vials and held for 180 days at three different temperatures—4 °C, 25 °C, and 40 °C—to examine how the particle size and zeta potential changed over time. Moreover, the drug entrapment efficiency (EE) versus storage period was calculated. The nanoparticle powders were re-dispersed in distilled water with a drug concentration of 1 mg/ml by vortexing for three minutes prior to the assessment of particle size, zeta potential, and entrapment efficiency.[3,4].

Stability Studies:
The constancy of optimized nano particles were established using in-vitro cytotoxicity profile.The procedure used for determining in-vitro cytotoxicity for the Cisplatin loaded PLGA nanoparticles and Cisplatin pure drug was repeated only for prepared and Optimized Cisplatin impregnated PLGA Nanosized particles at initial making time and after 2 months of preparation with total working time of 24hrs.The results were tabulated for the stability phenomena of the optimized nanoparticles [1,4].

Sterility Studies:
Bacteria and fungi were used as the positive and negative controls in a sterility investigation. Suitable media (Fluid Thioglycollate medium, Alternate Fluid Thioglycollate medium, and Soyabean casein digest media) were created, inoculated with Cisplatin Nanoparticles, and stored in an incubator while turbidity was tracked. This procedure involved the aseptic transfer of the specified amount of sample under test to three distinct fluid thioglycollate mediums (20 mL), alternate fluid thioglycollate mediums (20 mL), and soybean-casein digest mediums (20 mL). The mixture of nanoparticles and media was incubated for a minimum of 14 days at temperatures ranging from 300°C to 350°C for fluid thioglycolate medium, 20 mL for an alternate fluid thioglycolate medium, and 200°C to 250°C for soybean-casein digest medium. any microorganisms in the medium to grow was observed[5,6].

Cell culture
RPMI was used to cultivate the epithelial ovarian cancer cell line A2780. The cells were incubated at 37°C in a humid incubator with 5% CO2 and culture media supplemented with 10% FBS and 1X Antibiotic-Antimycotic solution.

in-vitro cytotoxicity by MT T Assay:
The cytotoxic effect of C-PLGA on cancer cell lines was determined using MTT cytotoxicity assay.

MTT assay :
By using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, the cytotoxicity of C-PLGA compounds on cell lines was evaluated (MTT assay). The amount of formazan produced as a result of the reduction of MTT by mitochondrial dehydrogenase enzymes is measured in this experiment to inadvertently assess the mitochondrial activity in living cells (1,2). In a nutshell, 96-well plates containing 5000 cells per well were treated in triplicates with increasing concentrations of cisplatin and c-PLGA before being incubated for 48 hours. Each well received

10 l MTT after incubation, which was added and incubated for 2 hours. The reaction is stopped by adding 100 l of stop solution, and the formazan crystals are then dissolved by incubating at 37 °C for two hours. On a Tecan endless 200 ELISA plate reader operating at 570 nm, the absorbance was measured As a vehicle control, DMSO was employed [7, 8]. With the aid of the GraphPad Prism 7 programme, the IC50 of the compounds was calculated after a 48-hour treatment. This formula was used to determine viability:
(((Absorbance of Sample)/((Absorbance of Control))*100) = Viability%

Experimental animal maintenance
For the tests, two-month-old, inbred Swiss albino mice with a typical body weight of 25–30 g were used. The animals were kept in open polypropylene enclosures, beddinged with rice husk, fed readily available food pellets (Shashank rat and micefeed, Bangalore), and given access to free RO-cleaned water. Throughout the exploratory time, the animal chamber was kept at a temperature of 270°C with a 12-hour light/dim cycle and was well ventilated. The Institute's creature morals council's regulations were followed as far as the conduct of animal testing was concerned. The Institutional Animal Ethics Committee supported the protocol used in this review for using mice as a creature model for malignant development (1953/PO/Re/S/17/CPCSEA).

Chromato graphic System:
high pressure liquid chromatography with a C-18 Column (250 mm x 4.6 mm) with particle size of 5 m (Schemadzu HPLC Class VP series). The Class-VP series version 5.03 software was installed on the HPLC system.

Construction of mobilephase:
HP LC grade methanol and acetonitrile were combined to create the mobile phase, which was then prepared by passing it through a 0.2-meter membrane filter and degassing it with helium for 15 minutes prior to use. This produced a column back pressure of 200-225 kg/cm. The temperature in the column was kept constant at 400C. 20 l of fluid were pumped into the loop[10,11].

Calibration curve:
10 mg of cisplatin were dissolved in 100 ml of a 15:85 combination of methanol and acetonitrile, then the solution was diluted to various concentrations to obtain different peak areas, such as 2g/ml, 4g/ml, 6g/ml, 8g/ml, 10g/ml, and 12g/ml.

Validation of the extraction process and analysis method for pure drugs in rat plasma:
methanol was used to dissolve 10 milligrammes of the medication. A calibration curve (RPHPLC) was established utilising the prepared serial dilutions (2, 4, 6, 8, 10 L) and blank plasma as the standard. The samples were statistically tested for linearity to determine the best fit. [11].

in-vivoKinetics:
Swiss albino mice were used to test the PLGA-Cis-NPs' in-vivo drug release. The mice were separated into three groups (n=4): Group-I, Group-II, and control. After treatment, blood samples were taken at intervals of 0 minutes, 5 minutes, 15 minutes, 30 minutes, 1 hour, 3 hours, 6 hours, 12 hours, 24 hours, and 48 hours. Group I was treated with the pure medication Cisplatin, while Group II was treated with PLGA-Cis-NPs (10 mg/kg, ip). Plasma was extracted from the collected blood samples using an ultracentrifuge, and it was then stored at -80°C pending further analysis. Using high performance liquid chromatography, the drug content was examined (HPLC)[12-13.]

TissueDistributionStudy For Cisplatin:
After 48 hours, the previously treated animals were slaughtered, and the major organs—liver, kidney, breast, heart, and spleen—were removed, homogenised, and the samples were ultra centrifuged before being extracted and evaluated using HPLC**.**[13].

in-Vitro CancerCell LineStudies :
The optimal formulation's anti-cancer properties were investigated using human cancer cell line models.
Morphological modifications demonstrated anti-cancer efficacy. The investigation of morphological alterations was conducted using a confocal microscope. Also, by inducing apoptosis, the anti-cancer activity was measured (in%). The percentage of apoptosis was calculated using flow cytometry (FCM).
By suspending minute particles, such as cells and chromosomes, in a stream of fluid and allowing them to pass past an electronic detecting device, FCM is a technique for counting and studying microscopic particles. It enables the multi parametric simultaneous investigation of the physical and/or chemical properties of up to thousands of particles per second. FCM offers a wide range of applications and is frequently used to diagnose medical conditions, including blood malignancies [14,15].

Human epithelial ovarian carcinoma cell lines resistant activity to cancer:
For this, the epithelial ovarian cancer cell line A2780 was chosen. Investigated was the impact of the optimum formulation on the induction of apoptosis (Programmed Cell Death) in A2780.
10% foetal bovine was added to RPMI medium, which was used to cultivate the cells. The cells

were kept in a humid atmosphere at 37 °C and 5% CO2. For the treatment, pills with the best formulation were dissolved in double-distilled water. In 6-well plates, cells were plated onto cover slips at a density of 1 X 104 per well. After twelve hours, the nutrient liquid was removed, and the medium was then supplemented with best formulation tablets at a final concentration of 100 g/ml and 200 g/ml. After a further 24 hours of incubation, the cells were treated with 10 SYTO 13 (Molecular Probes) for 20 minutes in full media at 37 °C to label the nuclei. The cover slips were mounted after being PBS-washed. A Zeiss 410 laser scanning confocal microscope was used to image the SYTO 13 fluorescence after it was stimulated by an argon-krypton laser with a 488 nm wave length and viewed through a 460 nm dichroic reflector and a 514 to 540 nm emission filter. Cell rupture, the development of apoptotic bodies, and deformed nuclei with conglomerated fluorescence giving the appearance of grains were the morphologic alterations that defined apoptosis. Deoxyuridine triphosphate and propidium iodide were used to label the cells, and the results were analysed using flow cytometry. [15].

EAC induced antitumour studies :

Kidwai Cancer Research Center supplied EAC cells (Bangalore, Karnataka). Swiss albino mice were transplanted with EAC cells intraperitoneally to maintain them in vivo. Every creature received intraperitoneal administration of the cancer cells that the phosphate cradle saline had suctioned from the mice's peritoneal depression in order to promote ascitic growth, with the exception of routine gathering. Swiss mice with pale skin have successfully completed a cancer prevention programme (8-10 weeks). The targeted review period was 10 days. Six mice from each of four groups of 24 Swiss mice with pale skin (24 2 grammes) were taken. All mouse groups other than the common group were injected with EAC cells into the intraperitoneal cavity, and treatment started 24 hours after growth inoculation. Animals (n=4) were arranged into the following groups: EAC-bearing mice were treated intravenously with cisplatin fluid (16 mg/kg) in groups I and II, respectively, while group IV's EAC-bearing mice were given cisplatin-PLGA (16 mg/kg)16,17,21. Each medication was started 24 hours after the growth vaccination and continued for 10 days continuously. Every day, the body weights of animals from all groups were recorded.

Estimation of biochemical parameters in serum and urine:

On 11th day, after 18hfasting, blood tests gathered from creatures. Blood tests were gathered through retro orbital plexuses to concentrate on the treatment impact on physiological capabilities. Blood without heparin was gathered for liver and kidney capability tests like Alanine amino transferase (AL T), Aspartate amino transferase (A ST) and Urea utilizing the isolated serum. Toward the finish of the study, mice were forfeited, and their liver and kidneys tests of two mice from each gathering were gathered for histopathologicalstudies [18,19].

Histo-pathological Research:

Each group's mouse liver and kidney tissues were treated with paraffin wax and preserved in 10% formalin. For histological evaluation, extremely thin segments were taken into consideration for hematoxylin and eosin staining, followed by appropriate examination with a light microscope. With the aid of a normalised convention, two segments from each animal were examined in order to identify the morphological characteristics associated with EAC-induced tumours. With a 22 mm FN magnifying lens, the "high power field (40x)" measures 0.237 mm2, and when investigating at 10 HPF, 2.37 mm2/slide has been taken into account. It was thought about how the liver and kidney components' histology changes. [22].

Statistic evaluation:

The mean SEM (n = 3) was used to express every value. One-way analysis of variance (ANOVA) was used to statistically examine the data from the different parameters, followed by Tukey-Kramer multiple correlation tests, and the mean values for each parameter were taken into consideration.[22].

3. Results & Discussion:

TABLE 1. Cistplatin nanoparticle stability study data kept at three different temperatures:

Sample	**4º±2ºC**	**25 º ±2 ºC 60% ± 5% RH**	**40 º ±2 º C 75% ± 5% R H**
Particle size (nm)			
Initial	167	167	167
6 month	168	167	167
12 month	168	168	169
Zeta potential (-mV)			
Initial	-25	-25	-24
6 month	-24	-23	-23
12 month	-24	-23	-22

Entrapment Efficiency (%)			
Initial	89	88	87
6 month	87	86	85
12 month	86	85	84

Stability Data using In-vitro Cytotoxicity Studies:

Stability is regarded as a crucial element in the creation of formulations since it is necessary for a flexible drug delivery carrier to exhibit carrier and encapsulation stability, which prevent premature drug release before reaching the target site. Due to the rigidity of their matrix/shell, PLGA-loaded nanoparticles have a reputation for being stable carriers. The findings of the present investigation revealed that the cytotoxicity effect of cisplatin-loaded nanoparticles was roughly comparable to the findings on the first day of synthesis, two months after the synthesis. FIG. 1 shows that the nanoformulation is sufficiently stable and can maintain the anticancer effects of cisplatin as a result..



FIG 1: A comparison of the cisplatin-loaded PLGA nanoparticles' lethal effects during manufacturing versus two months following synthesis. The information was presented as mean SD (n = 3).

TABLE 2: Cisplatin-loaded PLGA nanoparticles' IC50 cytotoxicity on the epithelial ovarian cancer cell line A2780 during manufacturing compared to two months following synthesis..

Stability of Cisplatin nanoparticles at initial production time IC_{50} (µM)	**Stability of Cisplatin nanoparticles After 2 months IC_{50} (µM)**
141.8±3.1	145.6±2.6

The information was presented as mean SD (n = 3).

Sterility Studies:

Till the conclusion of the 14th day of incubation, the sterility research of PLGA-Cis-NPs formulations in Fluid Thioglycollate medium, Alternate Fluid Thioglycollate medium, and Soyabean casein digest media did not exhibit any turbidity. According to the results, the formulations were sterile and did not encourage microbial growth.

FIG 2 :Sterility study with Staphylococcus Aureus by membrane filtration method for PLGA-Cis-NPs

FIG 3 :Sterility study with E.Coli by membrane filtration method for PLGA-Cis-NPs.

FIG 4 :Sterility study with Candida Albicans by membrane filtration method for PLGA-Cis-NPs.

Cytotoxicity assay:

Cisplatin and C-PLGA induced cytotoxicity on ovarian cancer cell lines:

The cytotoxic impacts of Cisplatin and an optimised formulation of C-PLGA on ovarian cancer cell lines i.e., A2780 was inspected by utilizing a standard cytotoxicity assay named MTT. The cells were submitted to MTT measurement after receiving varying doses of cisplatin and c-PLGA for 48 hours. Plan of Cisplatin and C-PLGA was regulated at different focuses going from 6.25 to 100 µg/ml against ovarian disease cell lines like A2780. Streamlined plan of C-PLGA was viewed as more deadly on A2780 when contrasted with Cisplatin alone which was displayed in Fig 3.1 and 3.2. The outcomes additionally showed that C-PLGA had more strength than Cisplatin which were communicated in Table 3. The cytotoxic impact of Cisplatin and C-PLGA were inspected and found to have IC50 values i.e., 38.53 µg/ml and 24.6 µg/ml individually.

TABLE 3: shows Cell viability percentage of Cisplatin and C-PLGA vs A2780 cells at varying concentrations

Conc. of Cisplatin, C-PLGA in µg/ml	Cisplatin vs A2780		C-PLGA vs A2780	
	Mean ± SEM	Cell viability %	Mean ± SEM	Cell viability %
Untreated	0.90±0.0035	100	0.90±0.0035	100
6.25	0.87±0.0053	94.92	0.86±0.0035	93.11
12.5	0.85±0.0049	86.75	0.66±0.0004	72.82
25	0.79±0.0035	78.2	0.52±0.0035	52.53

50	0.53±0.007	46.23	0.37±0.0056	33.87
100	0.35±0.0081	35.83	0.18±0.0084	16.36



FIG 5: MTT assay- cytotoxicity of Cisplatin against A2780 cells



FIG 6: MTT assay- cytotoxicity of C-PLGA against A2780 cells

FIG 5 & 6: Using the MTT assay, the effects of cisplatin and C-PLGA on ovarian cancer cell lines are evaluated. The cells were plated in 96-well dishes, incubated for 24 hours, and then exposed to Cisplatin and C-PLGA at increasing concentrations (6.25, 12.5, 25, 50, and 100 g/ml) for MTT tests for 48 hours. Cells that had been treated with DMSO were used as the vehicle control. At least three times were performed in each experiment.

FIG 7(a): Conc 6.25µg/ml

FIG 7(b): Conc 12.5µg/ml

FIG 7(c): Conc 25µg/ml

FIG 7(d):Conc 50µg/ml

FIG 7(e): Conc 100 µg/ml

FIG 7(f) : Control

FIG 7(a-f): MTT assay- cytotoxicity of C-PLGA with various concentrations against A2780 cells



FIG 7(g): Conc 6.25µg/ml

FIG 7(h): Conc 12.5µg/ml

FIG 7(i): Conc 25µg/ml



FIG 7(j): Conc 50µg/ml



FIG 7(k): Conc 100 µg/ml

FIG 7(l): Control

FIG 7(g-l): MTT assay- cytotoxicity of Cisplatin with various concentrations against A2780 cells

INVIVO RESULTS
In Vivo/Ex-Vivo Evaluation

TABLE 4: Cisplatin calibration curve via HPLC

Concentration ug/ml	Peak area 1	Peak area 2	Peak area 3	Meanpeak area	Std. Deviatation	% RSD
0	0		0	0	0	0
2	10240	10245	10255	10242	10240±7.637	0.22
4	18455	18475	18465	18461	18461±10	0.16
6	26155	26140	26145	26142	26141±5	0.05
8	35215	35210	35220	35215	35222±5	0.04
10	44125	44135	44115	44125	44113±7.637	5.19



FIG 8: Calibration curve of Cisplatin by HPLC

Calibrationcurve of Cisplatin by HPLC in Mouse plasma

The calibration curve was created using five injections that were repeated repeatedly over the course of three days—on average, fifteen injections. The stability of the plasma in the sample was examined concurrently. At -20 ºC, plasma was maintained. The standard curve was developed using concentrations ranging from 2 to 10 g/ml and was linear. The correlation coefficient R2 for the regression equation was calculated to be 0.998.

TABLE 5: Calibration curve of Cisplatin by HPLC in Mice plasma:

Concentration ug/ml	Peak area 1	Peak area 2	Peak area 3	Meanpeak area	Std. Deviatation	% RSD
0	0	0	0	0	0	0
2	10755	10285	10275	10280	10280±5	0.275
4	18874	18895	18885	18889	18888±8.544	0.506
6	27172	27185	27165	27175	27175±10.016	0.728
8	36926	36935	36925	36929	36929±3.5118	0.989
10	45150	45140	45105	45125	45125±5.0332	1.2104

(All the values were calculated as (Mean ±SD, n=3)



FIG 9: Standard curve in Mouseplasma

TABLE 6: Concentration of drug and Peak area for Cisplatin in Mouse plasma

Linearity(µg/mL)	2-10 (µg/ mL)
Slope(m)	4480.2
Regression r^2)	0.997
LOD(µg/ mL)	0.0014
LOQ(µg/ mL)	0.0028



FIG 10: Cmax of PLGA – Cis NPs in Mice plasma Chromatogram

Tissue Distribution Study For PLGA-Cisplatin Naoparticles:

According to the data, the kidney, spleen, heart, liver, lung, and breast were the organs with the most drug accumulation in the group that received only pure Ciplatin. The PLGA-Cis-NPs supplied to animal groups revealed that the breast, spleen, liver, lungs, kidney, and heart all accumulated the most medication. Pure substance Cisplatin exhibits more drug accumulation overall, especially at the kidney, as compared to all other groups

.

TABLE 7: Tissue distribution studies for Cisplatin in various organs

Organs	Conc (mcg/gm)	
	Cisplatin pure drug	PLGA-Cis-NPs
Lung	3.2±0.30	1.8±0.12
Liver	3.9±0.41	1.9±0.1
Spleen	4.3±0.13	1.8±0.30
Kidney	7.1±0.19	1.5±0.16
Heart	5.2±0.21	1.6±0.20
Breast	3.6±0.26	3.2±0.24



FIG 11: studies on the distribution of cisplatin in different organ tissues

Note: 1-Lungs, 2 - Liver, 3 –Spleen, 4 -Kidney, 5 - Heart, 6- Breast

in-vivo Pharmacokinetic Studies:

When the PLGA-Cis-NPs' in-vivo drug release was assessed, the drug release for the Cisplatin solution at 0 minutes was discovered to be 2.32 g/ml, and by the end of the sixth hour, we discovered 0.2 g/ml, but thereafter there were no drug releases found. The Cis-NPs did not exhibit any drug release until the 20th minute, and only then did we detect 0.07 g/ml for Cis-NPs. With Cis-NPs, the highest drug release was observed at the 12-hour mark and reduced thereafter. At the conclusion of the 48th hour, we discovered 0.6 g/ml. FIG. 12 displays the specifics.



FIG 12: In-vivo drug release of Cisplatin from Solution and NPs

Pharmacokinetic Parameters

The pharmacokinetic parameters were determined using PK solver using non compartment model. T1/2, Cmax, Tmax, AUC 0-t/0 -inf_obs, AUMC 0-inf_obs, MR T, Vd_obs and cl_obswas calculated free drug solution,Cis-NPs

TABLE 8: Pharmacokinetic profile of Cisplatin and C-PLGANPs

Parameters	**Cisplatin (mean ± SD)**	**C-PLGA NPs (mean ± SD)**
C_{max} (ng/m L)	132 ± 34	16 4 ± 16
T_{max} (hrs)	1	2
AUC_{last} (ng hrs/m L)	778 ± 271	1,73 8 ± 560[a]
AUC_{tot} (ng hrs/m L)	835 ± 289	1,8 88 ± 601[a]
Kel (hrs)	0.12±0.03	0.06±0.007[b]
$T_{1/2}$ (hrs)	6.2 2 ± 1.33	12.3 0 ± 1.40[c]
MR T (hrs)	8.5 2 ±1.31	16. 30 ± 2.38[b]
Relativebioavailability (%)	100	225 %
Notes: [a]P < 0.05 is a significant compared with standard. [b] P < 0.01 highly significant compared with normal. [c] P<0.001 extremely significant compared with normal		

Ovarian cancer cell line-specific anticancer activity:

After colouring the cells with SYTO 13, confocal microscopy revealed that the morphologic changes made by the optimal formulation, which induces apoptosis, were also noticeable. The nuclear morphology of A2780 cells treated with vehicle had no effect, whereas cells treated with GST formulation had brilliant fluorescent spots indicative of deformed nuclei appearing as conglomerated spots. Pictures 13.1 and 13.2 displayed these outcomes.

The apoptosis rates for the 100 g/ml and 200 g/ml dosages are 59.2% and 93.9%, respectively. FIGS. 13.3 and 13.4 displayed the cytometric graphs.

Fig 13: Photograph of Flow Cytometer.





Photograph 13.1 Morphology of Ovarian Cancer CellLine before Inductionof Apoptosis.



Photograph 13.2 Morphology of Ovarian Cancer CellLine afterInduction ofApoptosis.



Fig.13.3 Apoptosisof Ovarian cancercell lineby FlowCytometry at thedose of 100 µg/ml.



Fig. 13.4 Apoptosis of OvarianCancer CellLine by Flow Cytometry at theDose of 200 µg/ml.

Body Weight:

The Swiss albino mice received intraperitoneal delivery of EAC cells. In two groups of mice with EAC-induced growth, the treatments were started after 24 hours and continued after 10 days before perceptions and anticancer assessments were done. The body weight variations during the course of a 10-day treatment in mice with EAC-activated tumours are shown in TABLE 9. The increase in body weight brought on by the variety of ascites EAC prompted growth in mice was more when compared to normal mice ($p<0.01$), EAC+ Cisplatin and EAC + C-PLGA contrasted with EAC control mice with diminished body weight compared to disease control ($p<0.001$). Anyway the % body weight increment with C-PLGA was almost similar to free cisplatin.

TABLE 9: Body weights of various treatment groups of mice

Groups	Initial Body Weight(gm)	Final Body Weight(gm)	Percentage Increase In Body Weight
Normal Control	23.32 ± 0.13	25.56 ± 0.22	9.48
EAC Control	23.56 ± 0.14	29.36±0.32	17.26
EAC+ Cisplatin	23.76±0.36	25.16±0.36	8.69
EAC + C-Plga	23.76±0.12	25.57±0.39	9.26

Reduced tumor growth in EAC bearing mice:

EAC prompted Swiss albino mice models were utilized for concentrating on the in vivo movement of Cisplatin and C-PLGA. The gross appearance of the cancer tissue following 10 days of therapy showed huge contrast in growth size (FIG 14) in contrast with control cancer. The outcomes showed a huge decrease in cancer development in Cisplatin and C-PLGA treated mice when contrasted with untreated control mice tumor bearing growth (FIG 14 b,e and a,d). The outcomes showed a critical decrease in the cancer development in post-treated creatures when contrasted with controls. These outcomes demonstrate the way that C-PLGA can act better compared to free cisplatin as chemotherapeutic specialist in cancer treatment



FIG 14: Effect of Cisplatin and C-PLGA on EAC tumour model. EAC cells (1 x 106 cells/ animal) were injected to induce solid tumours. The above images represents a,d: Disease control mice and tumor; b,e: EAC +Cisplatin mice and tumor; c,f: EAC + C-PLGA mice and tumor.

Effect of Cisplatin and C-PLGA on serum biomarkers in EAC induced tumor mice.

Evaluation of serum biomarkers uncovered a sharp ascent in AST, ALT and BUN in the EAC control tumor (Group II) on comparison with development of growth and cell injury in normal mice ($P < 0.01$) along with increase in three traditional biomarker levels. Assessed levels of these boundaries are organized in TABLE 10. Nonetheless, C-PLGA diminished biomarkers level fundamentally ($P < 0.001$) when contrasted with Cisplatin alone presents expanded intensity and adequacy of C-PLGA towards growth.

TABLE 10: shows effect of Cisplatin and C-PLGA on serum biomarkers in EAC induced tumor mice

GROUPS	AST (U/L)	ALT (U/L)	BUN(mg/dl)
NORMAL	155.6 ± 2.06	56.40 ±2.18	32.02 ± 1.576
EAC INDUCED MICE	244.4 ± 8.17*	105.6 ± 3.43*	52.51 ± 1.488*
EAC MICE+CISPLATIN	217.2 ± 5.15##	84.40 ± 4.29##	48.85 ± 2.174##
EAC MICE+C-PLGA	176.6 ± 3.14##	73.20 ± 7.75##	38.56±2.34##

Presented values are in Mean ± SEM, (n=6)

* EAC-induced tumor in comparison to normal group ($p < 0.01$).

##Cisplatin and C-PLGA treated groups compared with EAC induced mice ($p < 0.001$).

Histo -pathological studies

The slides of the liver and kidney of the four treated groups were introduced in FIG. 15. The liver and kidney tissue of typical rodents gave no apparent indications of degeneration or rot and was recently affirmed from biochemical and cancer prevention agent results (Fig.15 A and E). Extensive liver haemorrhage, focal vein clog and kidney tissue degeneration alongside tubular necrosis was noted in the EAC mice (Fig.15 B and F). The mice which got Cisplatin showed diminished degeneration of hepatocytes and kidneys showed a rounded example through sensible corruption and degranulation (Fig.15 C and G), though C-PLGA treated mice liver displayed all around saved hepatic engineering with no signs of harm and kidneys showed gentle enlarging and irritation (FIG.15 D and H).



FIG 15: Histopathological analysis of organs after Cisplatin and C-PLGA treatment. At the end of the study, and organs were collected and used for histological analysis. A,B,C,D represents Liver of Control mice, EAC

induced mice, EAC+Cisplatin, EAC+C-PLGA ;E,F,G,H represents Kidney of Control mice, EAC induced mice, EAC+Cisplatin, EAC+C-PLGA

4. Discussion:

The obtained Stability results made evident that a small rise in particle size and reduction in zeta potential and entrapment efficiency were observed with storage time. The prepared nanoparticles were stable in all the temperature conditions.

When formulations were incubated for at least 14 days at 30 to 35 C for fluid thioglycolate medium and 20 to 25 C for soybean-casein digest medium during sterility testing, we discovered no signs of microbial development. Sterility test is passed by the preparation.

The plasma calibration curve (1-1,000 ng/mL) created in blank plasma was used to determine the concentration of cisplatin in the real mice samples. Table 5 displays the pharmacokinetic parameter data after i.p. administration of 10 mg/kg of cisplatin and an optimised formulation of C-PLGA. As shown in the data, Cisplatin-loaded PLGA NPs considerably (P 0.05) increased the extent of absorption (both AUC0-48 and AUC0-inf) compared to pure Cisplatin without significantly changing the rate of absorption (Cmax). This finding proved that Cisplatin-loaded PLGA NPs had a 2.25-fold higher bioavailability than unloaded PLGA NPs, with no appreciable impact on peak exposure. Moreover, the rate of elimination (Kel) for cisplatin-loaded PLGA NPs was significantly reduced (P0.01), followed by a highly significant rise in T1/2 (P0.001) and MRT (P<0.01) values. According to this finding, nanoparticles (optimised formulation) boost Cisplatin's bioavailability while also facilitating long-term retention, which may be advantageous for once-daily regimen treatment. Cisplatin was absorbed in this investigation at a higher rate and to a greater degree than was the case with free cisplatin.

Ovarian malignant growth is the most destructive gynaecologic infection and a really general wellbeing concern around the world. Drug poisonousness and sickness backslide stay as significant obstacles in the administration of ovarian malignant growth in spite of having progressed designated treatments . Cisplatin has shown anticancer property on an assortment of malignant growth types like colorectal disease, pancreatic malignant growth, cellular breakdown in the lungs, breast cancer, ovarian cancer, head and neck malignant growth, prostate disease and brain cancer .Nonetheless, improvement of Cisplatin as a medication is trying as it has shown least dependability and bioavailability in the in vivo framework . Our research validated anti ovarian cancer of A2780 cell lines in vitro. Cytotoxicity investigations of Cisplatin and C-PLGA on ovarian malignant growth cell lines have shown that it actuates poisonousness on disease cell lines. C-PLGA has better anticancer action contrasted with Cisplatin. The IC50 worth of Cisplatin and C-PLGA intensifies on ovarian disease cells was 38.53 µg/ml and 24.6 µg/ml which is ~20 fold better compared to the parent compound Cisplatin. Our improved plan of C-PLGA compound was viewed as more deadly on A2780 malignant growth cells.

Based on the great in vitro study results, we further continued to check the in vivo action of Cisplatin and advanced detailing of C-PLGA on EAC actuated growth bearing mice models. EAC (Ehrlich ascitic carcinoma) got from mice is generally utilized for in vivo investigations of against malignant growth compounds . EAC fills in all types of mice models forcefully which prompts neighborhood provocative reactions and makes reasonable in vivo condition to help cancer development. Cisplatin and C-PLGA treatment on EAC infused mice models showed a huge decrease in cancer development without unfavorable fundamental poisonousness. When contrasted with the past reports of in vivo anticancer action of Cisplatin, it showed promising outcomes at 10 mg/kg b.wt . Moreover, the harmfulness investigations of these detailing showed exceptional weight reduction in the treated mice contrasted with control animals. This may be expected to removable of ascites arrangement in the mice. Nephrotoxicity is one of the major antagonistic impact of Cisplatin. Alongside it, Cisplatin impact on liver was additionally examined . The liver and kidney harmfulness markers, for example, ALT, AST and Urea levels were close to typical, demonstrative of no fundamental poisonousness upon C-PLGA medicines than Cisplatin alone. This demonstrated that streamlined definition of C-PLGA lessened unfavorable impacts on liver and kidney with further developed strength in anticancer action.

5. Conclusion:

- The nanoformulation increased the therapeutic effects of cisplatin by 1.8-fold, which resulted in a decrease in the mean tumour size when compared to the standard cisplatin recipient mice. The nanoparticles increased the cytotoxicity effects of cisplatin against Ovarian cell adenocarcinoma cells (A2786) when compared to the standard cisplatin.
- The IC50 worth of Cisplatin and C-PLGA intensifies on ovarian disease cells was 38.53 µg/ml and 24.6 µg/ml which is better compared to the parent compound Cisplatin.

Our improved plan of C-PLGA compound was viewed as more deadly on A2780 malignant growth cells.

- Because of their ability to lessen the adverse effects of cisplatin, as well as its toxicity and therapeutic effects on cancer-bearing Albino mice, cisplatin-loaded PLGA nanoparticles can be seen as a prospective pharmacological candidate for the treatment of ovarian cancer.

Conflictsof Interest: The authors said they had no competing interests.

6. References:

Mohsen Ghaferi, Seyed Ebrahim Alavi, Hasan Ebrahimi Shahmabadi, Samar Amari, Bhalchandra Vivek Mohrir Aun Raza. Preparation, Characterization, and Evaluation of Cisplatin-Loaded Polybutylcyanoacrylate Nanoparticles with Improved In Vitro and In Vivo Anticancer Activities. www.mdpi.com/journal/pharmaceutics. (2020) 13 (44) :1-16.

Waks AG, Winer EP. Breast Cancer Treatment. JAMA. 2019 Jan 22;321(3):288.

Ayesha Siddiqua Gazi, Abbaraju Krishnasailaja, Preparation and Characterization of Methotrexate Loaded Polymeric Nanoparticles by Nanoprecipitation Technique, Nano Biomed Eng. (2019) 11(4), 351-360.

Seyed Ebrahim Alavi , Sitah Muflih Al Harthi , Hasan Ebrahimi Shahmabadi , Azim Akbarzadeh, Cisplatin-Loaded Polybutylcyanoacrylate Nanoparticles with Improved Properties as an Anticancer Agent, Int. J of Mol Sci. (2019) 20, 1-14

Xie Z, Zhang Y, Jin C, Fu D. Gemcitabine-based chemotherapy as a viable option for treatment of advanced breast cancer patients: a meta-analysis and literature review. Oncotarget. 2018 Jan 23;9(6).

Muhammad Asim Farooq, Md Aquib, Anum Farooq, Daulat Haleem Khan, Mily Bazezy Joelle Maviah, Mensura Sied Filli, Samuel Kesse, Kofi Oti Boakye-Yiadom, Rukhshona Mavlyanova, Amna Parveen, Bo Wang. Recent progress in nanotechnology-based novel drug delivery systems in designing of cisplatin for cancer therapy: an overview. Arti cells, nano med. Biotechno. (2019) 47(1); 1674–1692.

Mohsen Ghaferi, Seyed Ebrahim Alavi, Hasan Ebrahimi Shahmabadi, Samar Amari, Bhalchandra Vivek Mohrir, Aun Raza, Preparation, Characterization, and Evaluation of Cisplatin-Loaded Polybutylcyanoacrylate Nanoparticles with Improved In Vitro and In VivoAnticancer Activities, Pharmaceuticals.(2020) 13(44), 1-16. doi:10.3390/ph13030044www

Vasanthakumar S, Nazeer Ahamad KFH, Saha R N, in vitro and in vivo evaluation of paclitaxel loaded poly-(e-caprolactone), poly (dl-lactide-co-glycolide) and poly (dllactic acid)matrix nanoparticles in wistar rats, Nanomedicine I.(2013). 50, 259-270.

Cheng, J., Teply, B. A., Sherifi, I., et al. (2007) Formulation of functionalized PLGA- PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 28, 869–876.

Papasani MR, Wang G, Hill RA. "Gold nanoparticles: the importance of physiological principles to devise strategies for targeted drug delivery." Nanomedicine 2012;8(6):804-14

Ranoszek-Soliwoda K, Tomaszewska E, Socha E, Krzyczmonik P, Ignaczak A, Orlowski P, et al. The role of tannic acid and sodium citrate in the synthesis of silver nanoparticles. J Nanoparticle Res. 2017 Aug 4;19(8):273.

Mirzaei A, Janghorban K, Hashemi B, Bonyani M, Leonardi SG, Neri G. Characterization and optical studies of PVP-capped silver nanoparticles. J Nanostructure Chem . 2017 Mar 24;7(1):37–46.

Pharmacopoeia of India, Ministry of Health and Family Welfare, vol. 11, Controller of Publication, New Delhi, India, 2007

Dugandzic V, Hidi IJ, Weber K, Cialla-May D, Popp J. In situ hydrazine reduced silver colloid synthesis – Enhancing SERS reproducibility. Anal Chim Acta. 2016 Nov;946:73–79. (sterility test)

Iravani S, Korbekandi H, Mirmohammadi S V, Zolfaghari B. Synthesis of silver nanoparticles: chemical, physical and biological methods. Res Pharm Sci. 9(6):385–406(sterility test)

Gaihre B, Hee Lee Y, Seob Khil M, Keun Yi H, Yong Kim H. In-vitro cytotoxicity and cell uptake study of gelatin-coated magnetic iron oxide nanoparticles. J Microencapsul.2011 Jun 17;28(4):240–7.(celluar uptake).

Jamil A, Aamir Mirza M, Anwer MK, Thakur PS, Alshahrani SM, Alshetaili AS, et al.Co-delivery of gemcitabine and simvastatin through PLGA polymeric nanoparticles for the treatment of pancreatic cancer: in-vitro characterization, cellular uptake, and pharmacokinetic studies. Drug Dev Ind Pharm. 2019 May 4;45(5):745–53. (in-vivo tests).

Kattel K, Mondal G, Lin F, Kumar V, Mahato RI. Biodistribution of Self-Assembling Polymer–Gemcitabine Conjugate after Systemic Administration into Orthotopic Pancreatic Tumor Bearing Mice. Mol Pharm. 2017 May 7;14(5):1365–72.

Recordati C, De Maglie M, Bianchessi S, Argentiere S, Cella C, Mattiello S, et al. Tissue distribution and acute toxicity of silver after single intravenous administration in mice: nano-specific and size-dependent effects. Part Fibre Toxicol. 2015 Dec 29;13(1):12. (tissue distribution)

Chiriţă Cornel, Aurelia Nicoleta Cristea,Manuella Militaru3, Simona Negreş1, Cristina Elena Zbârcea1, Diana Camelia, "Pharmacological Evaluation Of Acute And Subacute Toxicity And Antidepressant Effect After Acute Administration Of Novel N -Substituted Benzamides" Farmacia, 58, 2010, 21-29.

Fuchs Tobias Christian, Frick, Katharina, Emde Barbara, Czasch Stephanie, Friedrich Von Landenberg, and Philip Hewitt, "Evaluation Of Novel Acute Urinary Rat Kidney Toxicity Biomarker For Subacute Toxicity Studies In Preclinical Trials " Toxicologic Pathology. 40, 2012, 1031-1048.

Y. S. R Krishnaiah , S. Satyanarayana , Y.V. Rama Prasad, S. NarasimhaRao. Evaluation of guar gum as a compression coat for drug targeting to colon. Int. J. Pharm. (1998) 171: 137–146.

H. Tozaki, J. Komoike, C. Tada, T. Maruyama, A. Terabe, T. Suzuki, A.Yamamoto, S. Muranishi. Chitosan Capsule for colon-specific drug delivery improvement of insulin absorption from the rat colon. J.Pharm.sci.86: (1997) 1016-1021.

J.L. Grem, M.Qim, A.S. Ismail. Cancer Chemo. Biomed Appl. 15 (2001).89.

Choi M, Cho M, Han BS, Hong J, Jeong J, Park S, et al. Chitosan nanoparticles show rapid extrapulmonary tissue distribution and excretion with mild pulmonary inflammation to mice. Toxicol Lett [Internet]. 2010 Nov;199(2):144–52.

Feng W, Nie W, He C, Zhou X, Chen L, Qiu K, et al. Effect of pH-Responsive Alginate/Chitosan Multilayers Coating on Delivery Efficiency, Cellular Uptake and Biodistribution of Mesoporous Silica Nanoparticles Based Nanocarriers. ACS Appl Mater Interfaces. 2014 Jun 11;6(11):8447–60.

Nair AB, Shah J, Al-Dhubiab BE, Patel SS, Morsy MA, Patel V, et al. Development of Asialoglycoprotein Receptor-Targeted Nanoparticles for Selective Delivery of Gemcitabine to Hepatocellular Carcinoma. Molecules. 2019 Dec 13;24(24):4566.

N K Marie. Preparation, evaluation and dissolution behaviors of water soluble drug loaded PLGA microspheres. Al – Mustansiriyah Journal of pharmaceutical Sciences (AJPS), 2007; vol 4(1): 23-31.

Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunological Methods. 1983; 65:55-63.

Abd Eldaim MA, Tousson E, El Sayed IE, Abd Elmaksoud AZ, Ahmed AA. Ameliorative effects of 9-diaminoacridine derivative against Ehrlich ascites carcinoma–induced hepatorenal injury in mice. Environmental Science and Pollution Research. 2021 May;28(17):21835-50.

Murugesan K, Koroth J, Srinivasan PP, Singh A, Mukundan S, Karki SS, Choudhary B, Gupta CM. Effects of green synthesised silver nanoparticles (ST06-AgNPs) using curcumin derivative (ST06) on human cervical cancer cells (HeLa) in vitro and EAC tumor bearing mice models. International Journal of Nanomedicine. 2019;14:5257.

Somani SM, Husain K, Whitworth C, Trammell G L, Malafa M, Rybak L P. Dose-dependent protection by lipoic acid against cisplatin-induced nephrotoxicity in rats: antioxidant defense system. Pharmacol Toxicol 2000; 86(5):234-41.

Salama AF, Tousson E, Ibrahim W, Hussein WM. Biochemical and histopathological studies of the PTU-induced hypothyroid rat kidney with reference to the ameliorating role of folic acid. Toxicology and industrial health. 2013 Aug;29(7):600-8.

Adebayo AH, Zeng GZ, Fan JT, Ji CJ, He WJ, Xu JJ, Zhang YM, Akindahunsi AA, Kela R, Tan NH. Biochemical, haematological and histopathological studies of extract of Ageratum conyzoides L. in Sprague Dawley rats. Journal of medicinal plants Research. 2010 Nov 4;4(21):2264-72.

Stewart C, Ralyea C, Lockwood S. Ovarian cancer: an integrated review. InSeminars in oncology nursing 2019 Apr 1 (Vol. 35, No. 2, pp. 151-156). WB Saunders.

Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. European journal of pharmacology. 2014 Oct 5;740:364-78.

Drayton RM, Catto JW. Molecular mechanisms of cisplatin resistance in bladder cancer. Expert review of anticancer therapy. 2012 Feb 1;12(2):271-81.

Islam M, Rahi M, Jahangir CA, Rahman MH, Jerin I, Amin R, Hoque KM, Reza MA. In vivo anticancer activity of Basella alba leaf and seed extracts against Ehrlich's ascites carcinoma (EAC) cell line. Evidence-Based Complementary and Alternative Medicine. 2018 Jan 1;2018.

Kubala M, Geleticova J, Huliciak M, Zatloukalova M, Vacek J, Sebela M. Na+/K+-ATPase inhibition by cisplatin and consequences for cisplatin nephrotoxicity. Biomedical Papers of

the Medical Faculty of Palacky University in Olomouc. 2014 Jun 1;158(2).

Jian Zhang, Tao Zhang, Xinyu Ti, Jieran Shi, changgui Wu, Xinling Ren, Hong Yin; Curcumin promotes apoptosis in A549/DDP multi drug – resistant human lung adeno carcinoma cells through an miRNA signaling pathway; Biochemical and Biophysical research communications; 399; 2010; pp.1-6.

Nihal Ahmad, Denise K. Feyes, Anna Liisa Nieminen, Rajesh Agarwal, Hasan Mukhtar; Green Tea Constituent Epigallocatechin-3-Gallate and Induction of apoptosis and Cell Cycle Arrest in Human Carcinoma Cells; Journal of the National Cancer Institute; 89; 24; 1997; pp.1881-1886.